Comparative Pharmacology
Head-to-head clinical analysis: GVS versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
GVS vs ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Combination antibiotic and corticosteroid: Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane permeability, and inhibit cell wall synthesis, respectively; hydrocortisone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
Apply 3-4 times daily to affected area as a thin layer. Topical route. Frequency: every 6-12 hours.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: 2-3h (systemic, IM); Bacitracin: 1.5h (systemic, IM); Polymyxin B: 6h (systemic, IV); Hydrocortisone: 1.5-2h (systemic). Topical: not applicable due to minimal absorption.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal: Neomycin (<1% absorbed, remainder fecal), Bacitracin (10-40% renal if absorbed, negligible), Polymyxin B (60% renal over 24h if absorbed), Hydrocortisone (metabolized, <1% unchanged renal; fecal for unabsorbed). Topical: negligible systemic absorption; fecal for unabsorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic